Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioAge Labs, obesity
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
IPO, MNTN and Ryan Reynolds
Ryan Reynolds's MNTN Explores Going Public as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, including Reynolds' MNTN.
Ryan Reynolds’s ad tech firm MNTN looks to Morgan Stanley for 2025 IPO
Reynolds became CCO of the firm after the company acquired his agency, Maximum Effort, in 2021. MNTN, a company that sells targeted TV advertising technology, may be working with Morgan Stanley on an initial public offering (IPO) as the firm considers its future.
Ryan Reynolds’ MNTN Is Said to Tap Morgan Stanley for 2025 IPO
MNTN, a connected TV advertising platform that counts Hollywood star Ryan Reynolds as its chief creative officer, has picked Morgan Stanley to work on an initial public offering, according to people familiar with the matter.
FierceBiotech
2d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
20h
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.
3d
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Helene death toll rises
Helene: How to help
Rescue mission launched
Courthouse attack: Charged
NC dam failure ‘imminent’
Troops to leave some bases
High-end brothel plea
Congestion fee bid denied
Houthis attack US warships
Bill to use birth control
AL sued over purging voters
ICE: Convicts roaming free
Diocese reaches settlement
UNC digital IDs blocked
Human rabies death in MN
US charges three Iranians
'Harry Potter' star dies
Van Gogh paintings attacked
Fed inflation gauge cools
NY ballot appeal rejected
KY sues Express Scripts
Congressional Gold Medal
Hezbollah leader killed
121st loss of the season
Dow closes at record high
Pleads not guilty
Deposition in AI suit
Feedback